GC
DYN icon

Guggenheim Capital’s Dyne Therapeutics DYN Stock Holding History

Guggenheim Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Sell
11,051
-1,185
-10% -$22K ﹤0.01% 1583
2026
Q1 		$222K Buy
12,236
+1,165
+11% +$20.1K ﹤0.01% 1495
2025
Q4 		$217K Sell
11,071
-36,609
-77% -$693K ﹤0.01% 1661
2025
Q3 		$603K Buy
47,680
+7,059
+17% +$80.5K ﹤0.01% 1106
2025
Q2 		$387K Sell
40,621
-3,059
-7% -$33.7K ﹤0.01% 1299
2025
Q1 		$457K Buy
43,680
+17,662
+68% +$253K ﹤0.01% 1235
2024
Q4 		$613K Sell
26,018
-5,839
-18% -$173K 0.01% 1168
2024
Q3 		$1.14M Buy
+31,857
New +$1.27M 0.01% 1030

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Guggenheim Capital's DYN Position: Q2 2026 in Review

Guggenheim Capital reduced its Dyne Therapeutics (DYN) stake by 9.7% in Q2 2026, selling an estimated $22K and leaving 11,051 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #1583.

Guggenheim Capital first reported a position in DYN in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.14M in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Guggenheim Capital held 11,051 shares of Dyne Therapeutics worth $245K as of Q2 2026.
  • Guggenheim Capital sold 1,185 Dyne Therapeutics shares in Q2 2026, an estimated $22K.
  • Dyne Therapeutics made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1583 holding.
  • Guggenheim Capital first reported a position in Dyne Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Guggenheim Capital's Dyne Therapeutics position peaked at $1.14M in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.